Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) CEO Dipal Doshi sold 1,000 shares of Entrada Therapeutics stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $15.99, for a total transaction of $15,990.00. Following the completion of the transaction, the chief executive officer now directly […]
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) CFO Kory James Wentworth sold 10,206 shares of the stock in a transaction on Friday, December 22nd. The shares were sold at an average price of $15.69, for a total value of $160,132.14. Following the sale, the chief financial officer now owns 49,571 shares in the company, […]
Entrada Therapeutics (NASDAQ:TRDA – Free Report) had its price objective reduced by HC Wainwright from $25.00 to $20.00 in a research report released on Monday morning, Benzinga reports. They currently have a buy rating on the stock. Entrada Therapeutics Stock Performance Shares of NASDAQ:TRDA opened at $12.97 on Monday. The firm has a market capitalization […]
By Colin Kellaher Entrada Therapeutics on Wednesday said the U.S. Food and Drug Administration declined to lift the clinical hold on a planned study of.